Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bertha Baum

Dermatology Hallandale Beach, FL Doctor of Osteopathy

NPI 1801162094 CMS profile 354368

1250 E Hallandale Beach Blvd, Suite 800, Hallandale Beach, FL 33009

Open in the dashboard

General payments

$297,963

790 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bertha Baum of Hallandale Beach, FL is reported in the CMS Open Payments database as having received $297,963 across 790 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $49,923 111
2024 General $35,782 89
2023 General $99,754 125
2022 General $45,950 121
2021 General $59,792 136
2020 General $4,620 90
2019 General $2,141 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bertha Baum
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Bertha Baum were reported at $49,923. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Bertha Baum Dermatology median Middle half National median
2019 $2,141 $454 $129–$1,240 $163
2020 $4,620 $235 $81–$756 $114
2021 $59,792 $377 $108–$1,108 $132
2022 $45,950 $514 $143–$1,391 $149
2023 $99,754 $607 $159–$1,674 $160
2024 $35,782 $751 $204–$1,903 $164
2025 $49,923 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $187,685 142 payments
  2. AbbVie, Inc. $99,272 168 payments
  3. Pfizer Inc. $977 48 payments
  4. Allergan Inc. $973 36 payments
  5. Genzyme Corporation $741 21 payments
  6. Merz North America, Inc. $695 12 payments
  7. Incyte Corporation $663 23 payments
  8. Regeneron Healthcare Solutions, Inc. $654 25 payments
  9. Sun Pharmaceutical Industries Inc. $640 34 payments
  10. VYNE Pharmaceuticals Inc. $563 30 payments
  11. Other $5,100 251 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $276,579 69 payments
  2. Food and Beverage $16,151 673 payments
  3. Travel and Lodging $4,803 45 payments
  4. Consulting Fee $350 1 payment
  5. Education $80 2 payments
Products named General payments · program years 2019–2025
  1. BOTOX $20,062 37 payments
  2. KYBELLA $1,950 1 payment
  3. SKYRIZI $1,198 60 payments
  4. DUPIXENT Immunology $785 22 payments
  5. OPZELURA $663 23 payments
  6. CIBINQO $647 36 payments
  7. HUMIRA $580 31 payments
  8. RINVOQ $495 22 payments
  9. DUPIXENT Inflammation And Immunology $421 17 payments
  10. Seysara $414 27 payments
  11. Other $10,430 515 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

135

Median for Dermatology: 534

Drug cost

$2,893

Median for Dermatology: $67,151

Branded share of claims

17.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rivastigmine Generic 12 $1,240
Triamcinolone Acetonide Generic 27 $342
Ketoconazole Generic 19 $290
Valacyclovir Valacyclovir Hcl Brand 24 $275
Dutasteride Generic 11 $259
Minoxidil Generic 16 $187
Nystatin Generic 11 $173
Mupirocin Generic 15 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$40,286

Medicare's payments for the services billed

Medicare patients

191

Average age 74

Services billed

1,007

131 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 50%
Osteoporosis 30%
Diabetes 26%
Ischemic heart disease 26%
Depression 19%
Chronic kidney disease 16%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $4,756
$4,756 — —
DUPIXENT
  • GENZYME CORPORATION $196
  • Regeneron Healthcare Solutions, Inc. $58
$254 — —
OPZELURA
  • Incyte Corporation $251
$251 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $188
$188 — —
LITFULO
  • PFIZER INC. $129
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

790 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record